CDK2 Mouse Monoclonal Antibody (Biotin conjugated) [Clone ID: OTI2A5]

CAT#: TA502915AM

CDK2 mouse monoclonal antibody, clone OTI2A5 (formerly 2A5), Biotinylated

Product Images

HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY CDK2 (RC200494, Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-CDK2. Positive lysates LY419741 (100ug) and LC419741 (20ug) can be purchased separately from OriGene.

• 

  Western blot analysis of extracts (35ug) from 14 cell lines by using anti-CDK2 monoclonal antibody (1:500).

• 

  Equivalent amounts of cell lysates (10 ug per lane) of wild-type 293T cells (WT, Cat# LC810293T) and CDK2-Knockout 293T cells (KO, Cat# LC810794) were separated by SDS-PAGE and immunoblotted with anti-CDK2 monoclonal antibody TA502915, (1:2000). Then the blotted membrane was stripped and reprobed with anti-HSP90AB1 antibody (TA500494) as a loading control.

• 

  Immunohistochemical staining of paraffin-embedded Adenocarcinoma of Human breast tissue using anti-CDK2 mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100°C for 10min, TA502915)

• 

  Immunohistochemical staining of paraffin-embedded Carcinoma of Human lung tissue using anti-CDK2 mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100°C for 10min, TA502915)

• 

  Anti-CDK2 mouse monoclonal antibody (TA502915) immunofluorescent staining of COS7 cells transiently transfected by pCMV6-ENTRY CDK2 (RC200494) (1:100).

• Immunofluorescent staining of HeLa cells using anti-CDK2 mouse monoclonal antibody (TA502915) (1:100).

• HEK293T cells transfected with either RC200494 overexpress plasmid (Red) or empty vector control plasmid (Blue) were immunostained by anti-CDK2 antibody (TA502915), and then analyzed by flow cytometry (1:100).

• Flow cytometric Analysis of Hela cells, using anti-CDK2 antibody (TA502915), (Red), compared to a nonspecific negative control antibody, (Blue) (1:100).

• Flow cytometric Analysis of Jurkat cells, using anti-CDK2 antibody (TA502915), (Red), compared to a nonspecific negative control antibody, (Blue) (1:100).

Show all 10 images

Specifications

Product Data

• Clone Name: OTI2A5
• Applications: FC, IF, WB
• Recommended Dilution: WB 1:2000, IHC 1:150, IF 1:100, FLOW 1:100
• Reactivities: Human, Mouse, Rat
• Host: Mouse
• Isotype: IgG2a
• Clonality: Monoclonal
• Immunogen: Full length human recombinant protein of human CDK2 (NP_001789) produced in HEK293T cell.
• Formulation: PBS (pH 7.3) containing 1% BSA, 50% glycerol and 0.02% sodium azide.
• Concentration: 0.5 mg/ml
• Purification: Purified from mouse ascites fluids or tissue culture supernatant by affinity chromatography (protein A/G)
• Conjugation: Biotin
• Storage: Store at -20°C as received.
• Stability: Stable for 12 months from date of receipt.
• Predicted Protein Size: 33.7 kDa
• Gene Name: cyclin dependent kinase 2
• Database Link:
  NP_001789
  Entrez Gene 12566 MouseEntrez Gene 362817 RatEntrez Gene 1017 Human
  UniProt ID P24941
• Background: The protein encoded by this gene is a member of the Ser/Thr protein kinase family. This protein kinase is highly similar to the gene products of S. cerevisiae cdc28, and S. pombe cdc2. It is a catalytic subunit of the cyclin-dependent protein kinase complex, whose activity is restricted to the G1-S phase, and essential for cell cycle G1/S phase transition. This protein associates with and regulated by the regulatory subunits of the complex including cyclin A or E, CDK inhibitor p21Cip1 (CDKN1A) and p27Kip1 (CDKN1B). Its activity is also regulated by its protein phosphorylation. Two alternatively spliced variants and multiple transcription initiation sites of this gene have been reported. [provided by RefSeq]
• Synonyms: CDKN2; p33(CDK2)

Reference Data

• Protein Families: Druggable Genome, Protein Kinase
• Protein Pathways: Cell cycle, Oocyte meiosis, p53 signaling pathway, Pathways in cancer, Progesterone-mediated oocyte maturation, Prostate cancer, Small cell lung cancer